CLINICAL_TRIALS
trial_result
· 2025-05-06
Clinical Trial Update: Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis [Phase 2]
Summary
Phase 2 safety update for Engensis (VM202) in participants with amyotrophic lateral sclerosis. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Helixmith Co., Ltd. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-06